The trial aims to evaluate the safety and efficacy of an experimental drug for the treatment of recurrent genital herpes caused by herpes simplex virus type 2 (HSV-2)
Currently the approved drugs to treat or to prevent recurrent genital herpes (RGH) do not always work 100%. Also, in order to prevent the recurrences, patients need to take multiple pills every day. The study medication showed strong activity against herpes viruses that cause genital herpes in the laboratory and it is now being tested to see if it would work to prevent RGH in people living with the condition.
This clinical trial aimed to identify the most effective dose(s) of the study medication in reducing recurrent genital herpes by measuring how much of the virus is present in swabs that are collected from participants.
This study is closed and no longer recruiting.
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by an Australian registered and certified HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2025). This statement protects the interests of people who agree to participate in human research studies.